sna | Media Room | PressRelease.com

Press Release Aug 13, 2020

Safety NetAccess, Inc. Creates 'HomeWorx' Product to Help Companies Manage the Work From Home Movement

Press Release Jul 8, 2020

Safety NetAccess, Inc. Creates SNA Event Productions Division, Appoints Martin Kwitschau Division President

Press Release Nov 13, 2018

Safety NetAccess, Inc. Establishes Resale Agreement With Phonesuite

Press Release Apr 25, 2012

Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA).

Repligen Corporation (NASDAQ:RGEN) today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of SMA.